Qualigen Therapeutics Inc (QLGN)
0.28
-0.01
(-5.07%)
USD |
NASDAQ |
May 21, 12:00
Qualigen Therapeutics Enterprise Value: 2.758M for May 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 20, 2024 | 2.758M |
| May 17, 2024 | 2.746M |
| May 16, 2024 | 2.780M |
| May 15, 2024 | 2.846M |
| May 14, 2024 | 2.714M |
| May 13, 2024 | 2.597M |
| May 10, 2024 | 2.692M |
| May 09, 2024 | 2.685M |
| May 08, 2024 | 2.665M |
| May 07, 2024 | 2.694M |
| May 06, 2024 | 2.745M |
| May 03, 2024 | 2.796M |
| May 02, 2024 | 2.728M |
| May 01, 2024 | 2.788M |
| April 30, 2024 | 2.788M |
| April 29, 2024 | 2.758M |
| April 26, 2024 | 2.730M |
| April 25, 2024 | 2.771M |
| April 24, 2024 | 2.846M |
| April 23, 2024 | 2.884M |
| April 22, 2024 | 2.76M |
| April 19, 2024 | 2.903M |
| April 18, 2024 | 2.863M |
| April 17, 2024 | 2.773M |
| April 16, 2024 | 2.788M |
| Date | Value |
|---|---|
| April 15, 2024 | 2.915M |
| April 12, 2024 | 2.992M |
| April 11, 2024 | 3.206M |
| April 10, 2024 | 3.294M |
| April 09, 2024 | 3.413M |
| April 08, 2024 | 3.304M |
| April 05, 2024 | 3.390M |
| April 04, 2024 | 3.328M |
| April 03, 2024 | 3.546M |
| April 02, 2024 | 3.420M |
| April 01, 2024 | 3.389M |
| March 28, 2024 | 3.420M |
| March 27, 2024 | 3.420M |
| March 26, 2024 | 3.427M |
| March 25, 2024 | 3.326M |
| March 22, 2024 | 2.983M |
| March 21, 2024 | 2.870M |
| March 20, 2024 | 2.832M |
| March 19, 2024 | 2.794M |
| March 18, 2024 | 2.833M |
| March 15, 2024 | 2.882M |
| March 14, 2024 | 3.064M |
| March 13, 2024 | 3.015M |
| March 12, 2024 | 3.068M |
| March 11, 2024 | 3.070M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.608M
Minimum
Dec 29 2023
122.67M
Maximum
Aug 05 2020
25.87M
Average
8.635M
Median
Enterprise Value Benchmarks
| Marizyme Inc | 29.33M |
| CEL-SCI Corp | 62.93M |
| AIM ImmunoTech Inc | 13.60M |
| IGC Pharma Inc | 33.12M |
| NovaBay Pharmaceuticals Inc | 7.267M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.450M |
| Total Expenses (Quarterly) | 2.274M |
| EPS Diluted (Quarterly) | -0.47 |
| Earnings Yield | -950.0% |
| Normalized Earnings Yield | -1159.54 |